Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.115 −25.8% OMI 0.300 −4.8% BMM 3.85 +1.3% CGD 0.630 +10.5% OCG 0.270 −3.6% CAMB 0.930 −7.0% HMR 0.590 −4.8% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.260 −1.9% GAL 0.395 −1.2% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.115 −25.8% OMI 0.300 −4.8% BMM 3.85 +1.3% CGD 0.630 +10.5% OCG 0.270 −3.6% CAMB 0.930 −7.0% HMR 0.590 −4.8% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.260 −1.9% GAL 0.395 −1.2%
M&A / Property

Cypher Metaverse Inc. Announces Acquisition and Financing

By The Northwire Desk — AI Analysis Oct 30, 2025 · 19:31 CODE · 1.2 Cypher Metaverse Inc.
CODE · Price

Executive Summary

  • Cypher Metaverse Inc. has signed a non‑binding LOI to combine with Texas‑based medical‑technology firm Noninvasix, Inc., creating a “Reverse Takeover” that would allow the combined entity to meet CSE industrial listing requirements.
  • The transaction will be executed via a three‑cornered amalgamation, share purchase, share exchange or other structure; Noninvasix shareholders will receive one common share of the resulting issuer for each Noninvasix share (1:1 exchange ratio).
  • A concurrent private placement is planned to raise at least US$3 million (CAD $0.40 per share) plus a separate non‑brokered private placement of up to CAD $250,000 (units at $0.33 with 2‑year warrants at $0.45).

Key Details

  • Transaction Structure:
  • Expected completion by three‑cornered amalgamation, share purchase, share exchange or alternate method as advised by legal and tax counsel.

  • Noninvasix will become a wholly‑owned subsidiary of Cypher; all outstanding Cypher warrants to be replaced with equivalent securities of the resulting issuer.

  • Exchange Ratio: 1 Noninvasix Common Share = 1 Common Share of the Resulting Issuer.

  • Management & Governance:

  • Post‑combination board and management will be determined by Noninvasix; details to be announced in future releases.

  • Cypher will rename itself at Noninvasix’s discretion, subject to CSE approval.

  • Private Placement Financing (Noninvasix):

  • Minimum gross proceeds: US$3 million.
  • Issue price: CAD $0.40 per Noninvasix Common Share.
  • Target investors: accredited investors and others under prospectus‑exempt exemptions.

  • Net proceeds earmarked for working capital and general corporate purposes.

  • Additional Private Placement (Cypher):

  • Up to CAD $250,000 of units at $0.33 each; each unit = 1 common share + 1 two‑year warrant (exercise price $0.45).
  • Proceeds for general corporate purposes.

  • Securities subject to a hold period of four months and one day from closing.

  • Bridge Loan:

  • Cypher may provide a secured bridge loan to Noninvasix at 8% annual interest, forgiven upon transaction completion; repayable within six months after termination of the definitive agreement.

  • Conditions to Closing:

  • Satisfactory due diligence, shareholder approvals, CSE listing approval, and successful completion of the private placements.

  • Trading Halt:

  • Cypher’s shares will be halted pending CSE review of the definitive agreement and fulfillment of CSE conditions for trading resumption.

  • Regulatory Filings:

  • A filing statement containing transaction details will be submitted to SEDAR in accordance with CSE policies.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Cypher Metaverse Inc.

Apr 30, 2026 · 17:00

Cypher Metaverse Secures Final Financing Tranche Ahead of Noninvasix Merger Closing

Financings Dec 22, 2025 · 17:35

Cypher Metaverse Inc. Announces Closing of Financing

Financings Dec 16, 2025 · 13:25

Cypher Metaverse Inc. Announces Signing of Definitive Agreement for Acquisition

Financings Jul 25, 2025 · 18:38

Cypher closes private placement

Financings